CONFIRMED: Johnson & Johnson is looking to buy a nearly $20 billion drugmaker

Johnson & Johnson is looking to buy the Swiss drugmaker Actelion in what could be a nearly $20 billion deal.

Actelion on Friday confirmed J&J’s interest, after Bloomberg first reported the potential takeover Thursday.

Shares of Actelion have jumped 16.7% to 184.40 Swiss francs ($182) since Thursday morning, giving the company a market cap of around 19.4 billion Swiss francs ($19.15 billion).

The two companies are in early talks, Bloomberg reported, and a deal may not necessarily materialise.

NOW WATCH: Richard Branson: Entrepreneurs need to fill the gap where government is lacking

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.